Transplantation & Cellular Therapy of ASTCT & CIBMTR 2023

BK Polyomavirus and Thrombotic Microangiopathy After Stem Cell Transplant: Current Knowledge and Unmet Needs
WHEN: February 19th, 2023, 12:15 p.m. -1:15 p.m.
WHERE: Product and Innovation Theater 1 (PIT Room 1)

  • Dr. Ben Laskin
  • Dr. Sonata Jodele
  • Dr. Steve Kleiboeker

Dr. Ben Laskin
Benjamin Laskin, MD, is Chief of the Division of Nephrology and an attending physician at the Children’s Hospital of Philadelphia. Dr. Laskin is also an Associate Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Laskin completed his undergraduate at Duke University where he graduated with a major in Economics. He attended the University of Maryland School of Medicine and completed his pediatrics residency and fellowship in pediatric nephrology at Cincinnati Children’s Hospital Medical Center.  Following his fellowship, he joined the faculty at the Children’s Hospital of Philadelphia. Dr. Laskin’s research interests are in infections and kidney disease in immunosuppressed children, including those receiving a bone marrow or solid organ transplant. He was the recipient of a K23 Career Development Award from the National Institutes of Health and currently is PI of an R01 designed to study viral and host predictors of hemorrhagic cystitis after bone marrow transplant.

Dr. Sonata Jodele
Sonata Jodele, MD is a Research Professor in the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children’s Hospital Medical Center.  Dr. Jodele’s clinical focus includes hematopoietic stem cell transplant and cell therapies for children and young adults. Her research interest centers on reducing organ toxicity after hematopoietic stem cell transplantation with a specific focus on hematopoietic stem cell transplant associated-thrombotic microangiopathy. Dr.Jodele leads national and international committees, NIH and industry sponsored clinical studies investigating TA-TMA pathogenesis, TA-TMA screening and early diagnostic tools, and studying novel therapeutic interventions for TA-TMA.

Dr. Steve Kleiboeker
Steven Kleiboeker, PhD, Vice President of Research and Development of Eurofins Viracor, is responsible for the scientific direction and oversight of the Company’s research and development programs, as well as the BioPharma and Clinical Trial Biomarker Services research businesses. Dr. Kleiboeker is board certified as a high-complexity laboratory director, technical supervisor and clinical consultant by the American Board of Bioanalysis. Dr. Kleiboeker has served as both principal investigator and co-investigator on numerous government-funded research grants (NIH, USDA). Dr. Kleiboeker received his PhD and DVM from the University of Missouri.


Development of a Multiplexed Quantitative PCR Assay for CD19-Directed CAR-T Cell Persistence Monitoring
WHEN: February 16th, 2023, 5:45 p.m. -6:45 p.m.
WHERE: Poster #LBA13
WHO: James Grantham


Visit booth #509 for “Meet the Scientist” sessions featuring leaders within Eurofins Transplant Diagnostics. Michelle Altrich, PhD, Steve Kleiboeker, PhD, and James Grantham will answer all of your questions about how we’re transforming the way people think about transplant diagnostics.